A project from the American Society of Retina Specialists
Sign in to view content
Avacincaptad Pegol, A Novel C5 Inhibitor, Demonstrates Continued Reduction in Geographic Atrophy Growth: 18-Month Results From GATHER1 Clinical Trial
- Video
- Published 2021
Related
Category: AMD-Non-Neovascular